Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084266 · ClinicalTrials.gov registry record · Phase 4
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,225
- Enrollment target
NCT00084266: Completed Phase 4 study, sponsored by Pfizer.
NCT00084266 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,225 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (136% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084266, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,225 participants
- Enrollment target
Study Summary
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.
Primary Outcome
Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent w
Interventions
- DRUG vancomycin
- DRUG linezolid (Zyvox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,225 participants |
| Start Date | 2004-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
What the finished NCT00084266 record still lists
NCT00084266 is an interventional study that assigns participants to a tested intervention. Its 1,225 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (136% higher).
The record links to 0 conditions, and to 2 interventions - of which vancomycin is the first listed.
NCT00084266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00084266 about?
NCT00084266 is a clinical study titled "Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)". To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphyloc...
What is the current status of trial NCT00084266?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,225 participants. The study started on 2004-10. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00084266?
The interventions under investigation include: vancomycin (DRUG), linezolid (Zyvox) (DRUG).
Who is sponsoring clinical trial NCT00084266?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00084266's enrollment target sits among peer trials
1,225 62nd of 2000 higher than 1,939 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia